Bibliographic Details
| Title: |
Very low doses of rituximab in autoimmune hemolytic anemia—an open-label, phase II pilot trial |
| Authors: |
Miriam M. Moser, Renate Thalhammer, Christian Sillaber, Ulla Derhaschnig, Christa Firbas, Ulrich Jäger, Bernd Jilma, Christian Schoergenhofer |
| Source: |
Frontiers in Medicine, Vol 11 (2024) |
| Publisher Information: |
Frontiers Media S.A., 2024. |
| Publication Year: |
2024 |
| Collection: |
LCC:Medicine (General) |
| Subject Terms: |
rituximab, CD20+ B cells, autoimmune hemolytic anemia (AIHA), cold agglutinin disease, warm autoimmune hemolytic anemia, Medicine (General), R5-920 |
| More Details: |
IntroductionAlthough rituximab is approved for several autoimmune diseases, no formal dose finding studies have been conducted. The amount of CD20+ cells differs significantly between autoimmune diseases and B-cell malignancies. Hence, dose requirements of anti-CD20 therapies may differ accordingly.MethodsWe conducted a phase II pilot trial investigating the effects and safety of very low doses of rituximab, i.e., 5 mg/m2 every 3 weeks, 20 mg every 4 weeks, 50 mg every 3 months (n = 3 each) and 100 mg every 3 months (n = 1) in patients with autoimmune hemolytic anemia (AIHA) to effectively suppress CD20+ cell counts. Doses were increased if circulating CD20+ cell depletion was insufficient (i.e., |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2296-858X |
| Relation: |
https://www.frontiersin.org/articles/10.3389/fmed.2024.1481333/full; https://doaj.org/toc/2296-858X |
| DOI: |
10.3389/fmed.2024.1481333 |
| Access URL: |
https://doaj.org/article/f5078ed6523a4ce0bc9992e69c004e1b |
| Accession Number: |
edsdoj.f5078ed6523a4ce0bc9992e69c004e1b |
| Database: |
Directory of Open Access Journals |
